Human pluripotent stem cell-derived cardiomyocytes

Differentiation Methods for Human Pluripotent Stem Cell-Derived Cardiomyocytes... [Pg.65]

MordwinkinNM, Burridge PW, Wu JC (2013) A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards. J Cardiovasc Transl Res 6(1)22-30... [Pg.75]

Braam SR, Tertoolen L, Casini S, Matsa E, Lu HR, Teisman A, Passier R, Denning C, Gallacher DJ, Towart R, Mummery CL (2013). Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. Stem Cell Res 10 48-56. [Pg.153]

HUMAN PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES A NEW PARADIGM IN PREDICTIVE PHARMACOLOGY AND TOXICOLOGY... [Pg.346]

HUMAN PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES... [Pg.348]

W. Keung, K. R. Boheler, R. A. Li, Developmental cues for the maturation of metabohc, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes. Stem Cell Res TherS, 17 (2014). [Pg.361]

S. S. Nunes, J. W. Miklas, J. Liu, R. Aschar-Sobbi, Y. Xiao, B. Zhang, J. Jiang, S. Masse, M. Gagliardi, A. Hsieh, Biowire a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods 10, 781-787 (2013). [Pg.362]

X. Yang, L. Pabon, C. E. Murry, Engineering adolescence maturation of human pluripotent stem cell-derived cardiomyocytes. CircRes 114, 511-523 (2014). [Pg.363]

Robertson C, Tran DD, George SC (2013) Concise review maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells 31 829-837 Romero L, Trenor B, Yang PC, Saiz J, Clancy CE (2015) In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome. J Mol Cell Cardiol 87 271-282... [Pg.199]

Ma JY, Guo L, Fiene SJ et al (2011) High purity human-induced pluripotent stem cell-derived cardiomyocytes electtophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 301(5) H2006-H2017... [Pg.73]

Rana P, Anson B, Engle S, Will Y (2012) Characterization of human-induced pluripotent stem cell-derived cardiomyocytes bioenergetics and utilization in safety screening. Toxicol Sci 130(1)417-131... [Pg.75]

Doherty KR, Talbert DR, Trusk PB, Moran DM, Shell SA and Bacus S (2015) Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types. Toxicol Appl Pharmacol. 285(l) 51-60. [Pg.8]

Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A (Aug 2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci 134(2) 412-426. [Pg.154]

Hayakawa T, Kunihiro T, Ando T, Kobayashi S, Matsui E, Yada H, Kanda Y, Kurokawa J, Furukawa T (2014). Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes correlation and complementarity with extracellular electrophysiology. J Mol Cell Cardiol 77 178-191. [Pg.154]

Leyton-Mange JS, Mills RW, Maori VS, Jang MY, Butte FN, Ellinor PT, Milan DJ (2014). Rapid cellular phenotyping of human pluripotent stem ceU-derived cardiomyocytes using a genetically encoded fluorescent voltage sensor. Stem Cell Rep 2 163-170. [Pg.155]

S, Sallam K, Knowles JW, Wang PJ, Nguyen PK, Bers DM, Robbins RC, Wu JC (2013). Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127 1677-1691. [Pg.155]

Rodriguez ML, Graham BT, Pabon LM, Han SJ, Murry CE, Sniadecki NJ (2014). Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts. 7 Biomech Eng 136(136) 051005. [Pg.157]

Martin CA, Huang CL, Matthews GD (2013) The role of ion chaimelopathies in sudden cardiac death implications for clinical practice. Ann Med 45 364-374 Meijer van Putten RM, MengareUi I, Guan K et al (2015) Ion chaimelopathies in human induced pluripotent stem cell derived cardiomyocytes a dynamic clamp study with virtual IKl. Front Physiol 6 7... [Pg.68]

Pointon A, Harmer AR, Dale IL et al (2015) Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sd 144 227-237... [Pg.196]

Scheel O, Freeh S, Amuzescu B et al (2014) Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology. Assay Drug Dev Technol 12 457-469... [Pg.199]

Kawamura, M., Miyagawa, S., Miki, K., Saito, A., Fukushima, S., Higuchi, T., et al., 2012. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 126 (ll(Suppl. 1)), S29-S37. [Pg.93]

Mandenius CF, Steel D, Noor F et al (2011) Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics a review. J Appl Toxicol 31(3)491-205... [Pg.75]

Zeevi-Levin N, Itskovitz-Eldor J, Binah O (2012) Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacol Ther 134(2)480-188... [Pg.75]

Yang L, Soonpaa MH, Adler ED et al (2008) Human cardiovascular progenitor cells develop from a KDR plus embryonic-stem-cell-derived population. Nature 453(7194) 524-526. Lian XJ, Hsiao C, Wilson G et al (2012) Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 109(27) E1848-E1857... [Pg.76]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...